招商国际的研究报告指，认为在推理大模型“平权化”的行业趋势下，讯飞医疗科技(02506.HK) 凭借对中国医疗行业的多年深耕以及在三大终端的产品协同优势，有望在医疗AI中持续保持长期竞争力。该行指，公司目前以26.1倍市销率和29.8倍市净率的估值倍数交易，高过中美可比公司水平。
该行指，公司近几年财务表现相对稳定，称2024年全年收入将按年增长高于前年。随着公司AI技术的不断叠代，收入来源正逐步由基层医院向等级医院转移，并同时带动患者端收入提升。同时，公司指出过去一年服务性收费的增长明显快于项目性收费，一次性收入占比也从91.5%降至80%以下，说明公司正从以项目为导向的思维逐渐转向以结果为导向的产品思维。在亏损上，公司表示2024年绝对值及亏损占比均在收窄。(vc/a)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.